TY - CHAP M1 - Book, Section TI - Chronic Leukemias A1 - Kiel, Patrick J. A1 - Fausel, Christopher A. A2 - DiPiro, Joseph T. A2 - Talbert, Robert L. A2 - Yee, Gary C. A2 - Matzke, Gary R. A2 - Wells, Barbara G. A2 - Posey, L. Michael PY - 2017 T2 - Pharmacotherapy: A Pathophysiologic Approach, 10e AB - Content UpdateDecember 12, 2017Long-Term Outcomes of Imatinib (GleevecĀ®) Treatment for Chronic Myeloid Leukemia: A follow-up study reported the long-term outcomes of the phase 3 International Randomized Study of Interferon and STI571 (IRIS) trial, which showed that imatinib was more effective and better tolerated than interferon alfa plus low-dose cytarabine in patients with newly-diagnosed chronic myeloid leukemia (CML) in the chronic phase. The follow-up study evaluated patients who had been randomized to receive imatinib; overall survival at 10 years was 83.3% with a median follow-up of 10.9 years. The discontinuation rate of imatinib due to adverse events (6.9%) was much lower than the interferon alfa plus cytarabine study arm (26.2%). These results show that the efficacy of imatinib 400 mg daily is maintained with a tolerable safety profile; imatinib and the second-generation tyrosine kinase inhibitors dasatinib and nilotinib are recommended as first-line therapy for patients with CML in chronic phase. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1150336130 ER -